Depletion of Treg cells accelerates the disease progression of SLE (5), while restoring Treg cell expansion by low-dose IL-2 treatment reduces the disease activity of SLE patients (6, 7), suggesting that increasing Treg cell expansion in vivo can be an effective method for SLE therapy. This evidence concerns the gene IL2 and systemic lupus erythematosus.